When Is Signatera Used?
Our commitment is to improve patient access to personalized and tumor-informed testing to help guide treatment decisions. Signatera is a tool that allows physicians to stratify their patients, closely monitor the effectiveness of adjuvant therapy and detect early relapse better than conventional tools. Signatera is a custom-built and tumor informed molecular residual disease (MRD) assay used to inform the presence of circulating tumor DNA (ctDNA), enabling physicians to get in front of disease or provide patients with much-needed peace of mind.
- Risk Stratification
After surgical resection to inform adjuvant treatment decisions
- Recurrence monitoring
To find early signs of cancer recurrence in patients with a previous cancer diagnosis
- Therapeutic response
To monitor the cancer’s response to treatment like immunotherapy (IO) on a molecular level
Reach out to Natera billing for support with coverage
- We welcome all insurance plans**
- We will work with patients so that cost is not a barrier for testing
- We offer an affordable cash pay rate for those patients who do not wish to use insurance (exclusions may apply)